BrainStorm will not provide ALS therapy under U.S. Right to Try act

BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing a failure to find a way to enable all patients to afford the treatment. The U.S.-Israeli company said on Tuesday it will focus on completing its advanced study for NurOwn in patients with amyotrophic lateral sclerosis (ALS) as quickly as possible. U.S. Congress last month approved the RTT bill that would allow terminally ill patients to try experimental treatments not yet approved by the Food and Drug Administration.